Theory Paper IIIDrNB Cardiology – Theory Notes

ADVANCES IN RESISTANT AND REFRACTORY HYPERTENSION

2-page exam answerLast reviewed: October 2026
Merit MedScript seal

IDEFINITIONS: RESISTANT VS. REFRACTORY HYPERTENSION

  • Resistant Hypertension (RH): Blood pressure (BP) that remains above 130/80 mmHg (or 140/90 mmHg depending on guidelines) despite the concurrent use of three antihypertensive agents of different classes (typically an ACEi/ARB, a Calcium Channel Blocker, and a Diuretic) at maximally tolerated doses.
  • Refractory Hypertension: A more severe phenotype in which BP remains uncontrolled despite at least five different antihypertensive agents, including a mineralocorticoid receptor antagonist (MRA) and a long-acting thiazide-like diuretic.

IIPHARMACOLOGICAL ADVANCES

  • Non-Steroidal Mineralocorticoid Receptor Antagonists (Finerenone):
    • Mechanism: Unlike Spironolactone, Finerenone is non-steroidal and more selective, with a lower risk of gynecomastia.
    • Evidence: The FIDELIO-DKD and FIGARO-DKD trials demonstrated cardiorenal protection in type 2 diabetes with CKD, with only modest BP lowering; it is not licensed as an antihypertensive.
    • Dual Endothelin Receptor Antagonists (Aprocitentan):
    • Mechanism: Inhibits endothelin-1 (blocking both ETA and ETB receptors), a potent vasoconstrictor elevated in resistant hypertension.
    • Evidence (PRECISION Trial): Showed that Aprocitentan significantly reduced BP in patients with resistant hypertension when added to standardized background therapy (FDA approved in 2024).
    • Aldosterone Synthase Inhibitors (Baxdrostat):
    • Mechanism: Directly inhibits the enzyme responsible for aldosterone synthesis rather than blocking the mineralocorticoid receptor.
    • Evidence (BrigHTN Trial): Demonstrated dose-dependent reductions in systolic BP in patients with resistant hypertension; the Phase III BaxHTN trial (NEJM 2025) confirmed a placebo-adjusted SBP fall of about 9 to 10 mmHg.

IIIDEVICE-BASED THERAPIES

  • Renal Denervation (RDN):
    • Technique: Radiofrequency- or ultrasound-based catheter ablation of the sympathetic nerves in the renal arteries.
    • Current Status: Following the SPYRAL HTN-ON MED and RADIANCE II trials, RDN is a Class IIb recommendation (ESC 2024) for patients with true resistant hypertension who are intolerant of or fail polypharmacy.
    • Carotid Baroreceptor Activation Therapy (BAT):
    • Technique: An implanted device (Barostim) that electrically stimulates the carotid baroreceptors, lowering central sympathetic outflow and increasing parasympathetic activity.
    • Evidence: Evidence comes mainly from the Rheos Pivotal Trial and registries (BeAT-HF studied heart failure, not hypertension); it is not routinely recommended.

IVSUMMARY OF LANDMARK TRIAL EVIDENCE

Trial Name Intervention / Agent Key Clinical Finding & Status
PATHWAY-2 Spironolactone vs. Bisoprolol or Doxazosin Confirmed Spironolactone as the most effective fourth-line agent for resistant hypertension
PRECISION Aprocitentan (Dual ERA) Significant BP reduction when added to standardized background therapy in resistant HTN
BrigHTN Baxdrostat (Aldosterone synthase inhibitor) Dose-dependent systolic BP reduction in resistant hypertension
SPYRAL HTN-ON MED & RADIANCE II Renal Denervation (RDN) (RF & Ultrasound) Proved the 24-hour “Always-On” BP reduction effect independent of medication adherence
SYMPLICITY HTN-3 (Long-Term) Multi-electrode RF Renal Denervation Neutral at 6 months, but 36-month follow-up showed larger, durable BP reductions with RDN vs sham

VTHE INDIAN CLINICAL CONTEXT

  • Biochemical Adherence Testing: Biochemical screening (urine or blood testing) for drug adherence is advocated before labeling a patient as having true refractory hypertension.
  • High Dietary Salt Sensitivity: Given the high salt intake in the Indian diet, long-acting Chlorthalidone is preferred over Hydrochlorothiazide as the thiazide-like diuretic of choice.
  • Role of Renal Denervation: Where long-term drug adherence is compromised by heavy pill burden, RDN is considered in high-risk patients with resistant hypertension.

Key references

  • Williams B, MacDonald TM, Morant S, et al. (PATHWAY-2 Investigators): Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2), The Lancet.
  • Schlaich MP, Bellet M, Weber MA, et al. (PRECISION Investigators): Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION), The Lancet.
  • Freeman MW, Halvorsen YD, Marshall W, et al. (BrigHTN Investigators): Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension, New England Journal of Medicine.
meritmedscript.comDr. Sidhartha Mullapudi

Was this answer useful?

Your rating helps decide which topics to expand next.

Report an error

Spotted something outdated or incorrect? Tell us and we will check it against the source.